Gilead Sciences (CHIX:GISD) Debt-to-Equity : 1.26 (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Gilead Sciences Debt-to-Equity?

Gilead Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €1,633 Mil. Gilead Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €19,315 Mil. Gilead Sciences's Total Stockholders Equity for the quarter that ended in Sep. 2024 was €16,645 Mil. Gilead Sciences's debt to equity for the quarter that ended in Sep. 2024 was 1.26.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Gilead Sciences's Debt-to-Equity or its related term are showing as below:

CHIX:GISd' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.72 Med: 1.27 Max: 1.73
Current: 1.26

During the past 13 years, the highest Debt-to-Equity Ratio of Gilead Sciences was 1.73. The lowest was 0.72. And the median was 1.27.

CHIX:GISd's Debt-to-Equity is ranked worse than
90.07% of 826 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs CHIX:GISd: 1.26

Gilead Sciences Debt-to-Equity Historical Data

The historical data trend for Gilead Sciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Debt-to-Equity Chart

Gilead Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

1.09

1.73

1.27

1.19

1.09

Gilead Sciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial															1.12	1.09	1.44	1.28	1.26

Competitive Comparison of Gilead Sciences's Debt-to-Equity

For the Drug Manufacturers - General subindustry, Gilead Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gilead Sciences's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Debt-to-Equity falls into.

Gilead Sciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Gilead Sciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1648.766	+	21264.313)	/	20937.861
	=	1.09

Gilead Sciences's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1632.612	+	19314.737)	/	16645.074
	=	1.26

Gilead Sciences (CHIX:GISd) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Gilead Sciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (CHIX:GISd) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Peru GILD:Mexico 1GILD:Italy 0QYQ:UK GIS:Germany GIS:Germany GIS:Germany GIS:Germany GILD:Chile GILD34:Brazil GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Gilead Sciences Headlines

No Headlines